CXCR1抗体—艾普蒂

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-2: Human colon cancer tissue, Human placenta tissue, Primary antibody: P10792(CXCR1 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes    

  
  

CXCR1 (C-X-C chemokine receptor type 1), also known as interleukin-8 receptor alpha (IL-8RA), is a G protein-coupled receptor (GPCR) that binds to chemokines such as IL-8 (CXCL8) and plays a critical role in mediating inflammatory responses. It is primarily expressed on neutrophils, endothelial cells, and certain cancer cells, where it regulates chemotaxis, immune cell activation, and angiogenesis. CXCR1 signaling is implicated in chronic inflammation, autoimmune diseases, and tumor progression, particularly in promoting metastasis and resistance to therapy in cancers like breast and melanoma.

CXCR1 antibodies are essential tools for studying receptor expression, localization, and function in both research and clinical contexts. These antibodies are designed to target specific extracellular or intracellular epitopes of CXCR1. enabling applications such as flow cytometry, immunohistochemistry, Western blotting, and functional assays. Monoclonal antibodies (e.g., clones 42705 and 8F1) are widely used for their specificity, while polyclonal antibodies offer broader epitope recognition. Commercially available from suppliers like R&D Systems, Abcam, and BioLegend, they aid in elucidating CXCR1's role in disease mechanisms and therapeutic targeting.

Therapeutic interest in CXCR1 inhibitors, including neutralizing antibodies and small molecules, has grown due to their potential to block pro-inflammatory or pro-tumorigenic pathways. For instance, reparixin, a CXCR1/2 antagonist, has undergone clinical trials for inflammatory conditions and cancer. CXCR1 antibodies also serve as biomarkers in disease prognosis, reflecting receptor upregulation in pathological states. Challenges remain in ensuring antibody specificity, minimizing cross-reactivity with CXCR2 (a closely related receptor), and optimizing therapeutic efficacy with minimal off-target effects. Ongoing research continues to explore CXCR1's dual role in immunity and disease, driving innovation in antibody-based diagnostics and therapies.